Sodium Stibogluconate

Mechanism :

Exact mechanism of action is unknown. Proposed mechanisms include conversion to trivalent form of antimony that affects glucose metabolism, fatty acid beta oxidation, and adenosine triphosphate (ATP) formation.

Indication :

Leishmaniasis: cutaneous, mucosal and visceral leishmaniasis.

Contraindications :

Hypersensitivity, Significant renal impairment; breast-feeding.

Dosing :

IM, IV:

20 mg/kg/day. Duration of therapy is 20 days for cutaneous leishmaniasis and 28 days for mucosal and visceral leishmaniasis.

Adverse Effect :

Diarrhea, nausea, vomiting, Flattened T wave, inversion T wave, prolonged Q-T interval, Headache, lethargy, malaise, Abdominal pain, anorexia, increased serum lipase and amylase, depressed bone marrow (transient), Arthralgia, myalgia.

Interaction :

Amphotericin B: May enhance the cardiotoxic effect of Sodium Stibogluconate.
QT-prolonging Agents like Antidepressants, Antipsychotics, Class 1C Anti-Arrhythmic, Kinase Inhibitors, Quinolone Antibiotics: May enhance the QTc-prolonging effect of Sodium Stibogluconate.

Hepatic Dose :

Avoid use.